The modulation of such mechanisms presents a promising strategy, not only for the additional treatment of SMA patients in which splicing correction of SMN2 is not sufficient but also other motor neuron diseases like ALS. The gene discussed is SMN2; the disease is amyotrophic lateral sclerosis.